Last updated on October 2018

Study of the Effect of Velaglucerase Alfa (VPRIV ) on Bone-related Pathology in Treatment-na ve Participants With Type 1 Gaucher Disease

Brief description of study

The primary purpose of this study is to evaluate the effect of VPRIV therapy (60 units per kilogram [U/kg] every other week [EOW]) in treatment-naive participants with type 1 Gaucher disease on change from baseline in lumbar spine (LS) bone mineral density (BMD) Z-score as measured by DXA after 24 months of treatment.

Clinical Study Identifier: NCT02574286

Contact Investigators or Research Sites near you

Start Over

Shire Contact

Kaiser Permanente
Los Angeles, CA United States
  Connect »

Priya Kishnani, MD

Duke University Medical Center
Durham, NC United States
  Connect »

Can Ficicioglu

The Children's Hospital of Philadelphia
Philadelphia, PA United States
  Connect »

Jesus Villarrubia Espinosa, MD, PhD

Hospital Universitario Ramon y Cajal
Madrid, Spain
  Connect »

Pilar Giraldo, MD

Hospital Quironsalud Zaragoza
Zaragoza, Spain
  Connect »

Patrick B Deegan, MD

Addenbrooke's Hospital
Cambridge, United Kingdom
  Connect »

Derralynn A Hughes, MD

Royal Free Hospital
London, United Kingdom
  Connect »

Joel Charrow, MD

Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, IL United States
  Connect »

Shire Contact

Cedars Sinai Medical Center
Beverly Hills, CA United States
  Connect »

Jaime Vengoechea Barrios, MD

Emory Genetics
Atlanta, GA United States
  Connect »

Heather Lau, MD

NYU School of Medicine
New York, NY United States
  Connect »

Hagit Baris Feldman

Rambam Health Care Campus
Haifa, Israel
  Connect »

Ari Zimmerman, MD

Shaare Zedek Medical Center
Jerusalem, Israel
  Connect »

Noa Ruhrman Shahar

Rabin Medical Center
Petah Tikva, Israel
  Connect »